🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Plasma Cell Disorder

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype NCT07341867Phase 11 site📍 Boston Andrew Hantel, MD · Tests: Dexamethasone, Bortezomib, LENALIDOMIDE, Daratumumab, Carboplatin A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 NCT07623798Phase 31 site📍 Shanghai Innovent Biologics (Suzhou) Co. Ltd. · Tests: Pomalidomide Capsules, Bortezomib for Injection, Daratumumab Injection (Subcutaneous Injection), IBI3003, Selinexor Tab… A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) NCT05519085Phase 3266 sites📍 Los Alamitos📍 San Diego📍 West Hollywood Celgene · Tests: mezigdomide, Pomalidomide, Bortezomib, Dexamethasone Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma NCT05530421Phase 23 sites📍 Coral Gables📍 Deerfield Beach📍 Miami University of Miami · Tests: Selinexor, Venetoclax, Dexamethasone Sleep Apnea in Patients With MGUS and MM NCT04114084n/a1 site📍 Iowa City Michael Tomasson · Tests: Bone Marrow Aspirate and Biopsy Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma NCT06182774Phase 331 sites📍 Edmonton📍 Kelowna📍 Vancouver Canadian Cancer Trials Group · Tests: Daratumumab, Lenalidomide, Dexamethasone, Isatuximab A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies NCT05908409Phase 1, Phase 211 sites📍 Santander📍 Salamanca📍 Barcelona IDP Discovery Pharma S.L. · Tests: IDP-121 SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders NCT07850284n/a1 site📍 Rochester Mayo Clinic · Tests: Non-Interventional Study SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265Phase 15 sites📍 Denver📍 Atlanta📍 Fairway Verismo Therapeutics · Tests: SynKIR-310 Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients NCT07110636NA6 sites📍 San Francisco📍 New Orleans📍 Boston Karius, Inc. · Tests: Metagenomic plasma-based test for agnostic pathogen detection MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma NCT07106736Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: BCMA CAR-T, GPRC5D/CD3 BiTEs A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) NCT07227311Phase 259 sites📍 Los Alamitos📍 Torrance📍 Whittier GlaxoSmithKline · Tests: Belantamab mafodotin, Dexamethasone, Pomalidomide, Bortezomib, Carfilzomib Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure NCT07085728Phase 21 site📍 Anchorage Eastern Cooperative Oncology Group · Tests: Cyclophosphamide, Bortezomib (VELCADE), Dexamethasone, Daratumumab-hyaluronidase Effects of Controlled Breathing Added to Therapeutic Exercise in Multiple Myeloma NCT07312942NA1 site📍 Madrid Universidad Complutense de Madrid · Tests: Controlled breathing exercise protocol + therapeutic exercise + initial education session, Therapeutic exercise + initi… A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma NCT04973605Phase 1, Phase 274 sites📍 Birmingham📍 Duarte📍 Irvine BeOne Medicines · Tests: Sonrotoclax, Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies NCT07101705EARLY Phase 11 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: OriV508 Injection Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810Phase 12 sites📍 Scottsdale📍 Rochester Mayo Clinic · Tests: Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). NCT07638683Phase 21 site📍 Shanghai Shanghai Zhongshan Hospital · Tests: Teclistamab Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing NCT06550427n/a1 site📍 Taipei National Taiwan University Hospital · Tests: ctDNA analyzed by phased variant Wisconsin Ginseng for Decreasing Cancer Related Fatigue NCT06395441Phase 315 sites📍 Albert Lea📍 Bemidji📍 Brainerd Mayo Clinic · Tests: American Ginseng, Placebo Administration, Questionnaire Administration Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma NCT04840602Phase 2146 sites📍 Tucson📍 Tucson📍 Irvine National Cancer Institute (NCI) · Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia NCT05640102n/a8 sites📍 Huntsville📍 Mobile📍 Duarte BeiGene · Tests: Zanubrutinib Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis NCT06699394NA2 sites📍 Beijing📍 Beijing Peking University People's Hospital · Tests: Teclistamab (Tec) A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" NCT07382739Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Elranatamab Use of BMAC With Hip Arthroscopy Treatment of FAI and Labral Tear NCT03909139n/a1 site📍 Boston Massachusetts General Hospital · Tests: BMAC Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies NCT05887167Phase 11 site📍 Los Angeles Joshua Sasine, MD, PhD · Tests: autologous hematopoietic stem cells added to planned CAR T Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma NCT07657312Phase 21 site📍 Columbus Naresh Bumma · Tests: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Infliximab, Positron Emission Tomography Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration NCT07115667Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: BCMA/CD3 bispecific antibody (CM336) Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) NCT06759181Phase 1, Phase 21 site📍 Xuzhou Xuzhou Medical University · Tests: anti-BCMA/FcRL5 CAR T
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy